North China Pharmaceutical Company.Ltd (SHSE:600812 Investor Three-year Losses Grow to 51% as the Stock Sheds CN¥412m This Past Week
North China Pharmaceutical Company.Ltd (SHSE:600812 Investor Three-year Losses Grow to 51% as the Stock Sheds CN¥412m This Past Week
If you love investing in stocks you're bound to buy some losers. But the long term shareholders of North China Pharmaceutical Company.Ltd (SHSE:600812) have had an unfortunate run in the last three years. Sadly for them, the share price is down 52% in that time.
如果你喜歡投資股票,你肯定會買到一些失敗者。 但是華北製藥股份有限公司(SHSE: 600812)的長期股東在過去的三年中運行不佳。不幸的是,股價在那段時間下跌了52%。
After losing 4.6% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.
在過去的一週中下跌了4.6%之後,值得調查該公司的基本面,以了解我們可以從過去的表現中推斷出什麼。
We don't think that North China Pharmaceutical Company.Ltd's modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. It would be hard to believe in a more profitable future without growing revenues.
我們認爲華北製藥股份有限公司不起眼的過去十二個月的利潤並沒有吸引市場的全部關注。我們認爲營業收入可能是一個更好的指引。一般來說,我們認爲這種公司更可比較於虧損的股票,因爲實際的利潤非常低。未來的盈利能力不斷擴大,如果沒有增加營業收入,將很難相信更具盈利能力的未來。在過去的三年中,華北製藥股份有限公司的營業收入每年下降了3.1%。這不是一個好的結果。由於營收下降,利潤只是一個夢想,我們可以理解爲什麼股價每年下降15%。儘管如此,如果未來存在增長,現在可能是該公司的低潮。在它實現盈利之前,我們對這個公司還是持謹慎態度,因爲我們不專門研究扭轉形勢的機會。
Over the last three years, North China Pharmaceutical Company.Ltd's revenue dropped 3.1% per year. That is not a good result. With revenue in decline, and profit but a dream, we can understand why the share price has been declining at 15% per year. Having said that, if growth is coming in the future, now may be the low ebb for the company. We'd be pretty wary of this one until it makes a profit, because we don't specialize in finding turnaround situations.
在過去的三年中,華北製藥公司的營業收入年均下降3.1%。這不是一個好結果。營收下降,利潤只是一場夢,我們可以理解爲什麼每年的股價下跌15%。話雖如此,如果未來有增長將會到來,現在可能是公司的低谷。在公司盈利之前,我們對此感到非常謹慎,因爲我們不專門研究企業扭虧爲盈的情況。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的圖表顯示了收益和營收隨時間的變化情況(通過單擊圖像揭示確切的值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240525/0-d4f0d2dbd8068d69f98f2f51ca34a3d1-0-49b9f6d22de05164a0e945e459d736da.png/big)
It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. It might be well worthwhile taking a look at our free report on North China Pharmaceutical Company.Ltd's earnings, revenue and cash flow.
值得一提的是,該公司的首席執行官的薪酬低於類似規模的公司的中位數。但是,雖然首席執行官的報酬總是值得檢查,但真正重要的問題是該公司能否在未來增加盈利。查看我們的關於華北製藥股份有限公司的盈利、營業收入和現金流的免費報告,可能會非常值得。
A Different Perspective
不同的觀點
We regret to report that North China Pharmaceutical Company.Ltd shareholders are down 19% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 8.9%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 3%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand North China Pharmaceutical Company.Ltd better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with North China Pharmaceutical Company.Ltd (at least 1 which can't be ignored) , and understanding them should be part of your investment process.
我們很遺憾地報告說,華北製藥股份有限公司股東今年下跌了19%(包括分紅在內)。不幸的是,這比更廣泛的市場下跌8.9%還要糟糕。但是,股價受到更廣泛市場的影響可能只是因爲市場動盪。如果基本數據有良好的機會,值得注意。長期投資者不會太難過,因爲他們每年都會獲得3%的回報,在五年內。最近的拋售可能是一個機會,因此值得查看基本數據以了解長期增長趨勢的跡象。長期跟蹤股價表現總是很有趣的。但是要更好地了解華北製藥股份有限公司,我們需要考慮許多其他因素。例如,考慮投資風險這個永恒的威脅。我們已經確定了華北製藥公司的2個風險警示(不能忽視的至少有1個),了解它們應該是您投資過程的一部分。
For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.
對於那些喜歡尋找獲勝投資的人來說,最近有內部購買的低估公司免費列表可能是一個很好的選擇。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。